consensus to gain access before

Management, pulmonologists and respiratory patients agree that it should improve access to pharmaceutical innovation in this environment. This is how he was raised at the table “Improving access to pharmacological innovations” held at the Separ Institutional Strategic Forum, FEIS 2022. “After the drugs are approved, The goal is to reach almost all patients who have indications for their pathologies for these treatments,” he assured Juan Luis Garcia Riverogeneral secretary of the Spanish Society of Pneumology and Thoracic Surgery during a conference convened by the scientific society and organized by Medical Writing.

In a meeting held thanks to the collaboration of the Spanish Federation of Healthcare Technology Companies (Fenin) and its respiratory therapy group (Air Liquide Healthcare, Esteve Teijin, Linde, Oximesa Nippon Gases, Sapio Life and Vivisol), Boehringer Ingelhem; García Rivero, who works as a specialist pulmonologist at the Hospital Marqués de Valdecilla (Santander), pointed out disparity in drug approval rates which have received the approval of the European Medicines Agency (EMA, acronym in English) in one area or another.

In that sense, Mariano pastor Sanzthe president of the Spanish Federation of Associations of Patients with Allergies and Respiratory Diseases (Fenaer), stated that “the patient must have access to all pharmacological innovations in which A lot of financial and human resources have been invested for its development”. For this reason, he complained that in Spain “it takes time to access medicines that have been approved more than 500 days and of the total number approved by the EMA, only 50 percent are approved here. If we compare with Germany, we are quite late“.

Mariano Pastor Sanz, president of the Spanish Federation of Associations of Patients with Allergies and Respiratory Diseases (Fenaer), calls for the acceleration of the arrival of innovative drugs for respiratory diseases.

from his position, Carmen Encinas BarriosDirector General of Health Planning, Management and Inspection of the Ministry of Health of Castilla-La Mancha, stated that “tries to ensure equality and access new treatments throughout the territory”. In addition, Encinas emphasized that the process of creating a drug until it reaches the patient is “a long and complex process, in which important decisions must be made and safely in each and every step there are aspects of improvement“, he pointed out in the table moderated by Esther Ortega Echevarría, head of the Specialties Department Medical writing.

The inspection visa, a key tool for controlling the prescription of medicines, is one of the most commented aspects. President of Fenerbahçe he labeled the visa “congestive” and “inconvenient” for patients and advocated its “elimination”. In his opinion, this element makes it difficult to access medicines that have already shown their scientific evidence. However, Encinas appreciated the relief’s function, although he clarified it “It cannot be a problem, and if it is, it must be improved”as well as other possible access barriers.

Carmen Encinas Barrios, General Director of Planning, Management and Sanitary Inspection of the Ministry of Health of Castilla-La Mancha, participated in the table electronically.

Financing and prioritization of pathologies

Encinas explained the process in which it is decided how an innovative drug will be financed, which takes place in the Inter-Ministerial Commission for the Prices of Medicines and Health Products. at these meetings a decision is made to finance the drug or not new and how it will be implemented. In this regard, García pointed out that “the prevalence of respiratory diseases i the influence is very broad dedicate the resources it deserves”.

The general secretary of Separa claims that there is in Spain structure for attracting foreign financing and maintain national funds in the country to “help the advancement of innovative medicines and the patients involved in clinical trials could benefit from them”, because sometimes there is no other alternative. “The key is in that research has muscle meet all these needs”, added Encinas.

For his part, the pastor pointed out that “every pathology is important and everyone deserves a cure” and made it clear that the perception of the entity it represents is such innovation deals with all pathologies equally, although it would be good to give priority to those who have progressed less in recent years.

On this issue, Encinas emphasized that the pharmacological innovation plan “must go hand in hand with prioritize unmet medical needs“, putting the tools in place to pave the way for those who don’t have the means to face their disease and get it as soon as possible.

Juan Luis García Rivero, Secretary General of Separa and specialist pulmonologist at Marqués de Valdecilla Hospital (Santander), confirms that training innovation specialists is “a task for everyone”.

Training of experts

A challenge for training and evaluation of innovative medicinesboth in the field of care and management, the pulmonologist is “a task for everyone and everything”, described the General Director of Health Planning, Management and Inspection of the Ministry of Health of Castilla-La Mancha.

In the same vein, a specialist pulmonologist at Marqués de Valdecilla Hospital commented that the training “of fundamental importance for bringing the clinical trial to the patient” and that the professional is up to date. The pastor insisted that the training must be conducted by scientific societies and made himself available to them and the public administration “in order to everything we can contribute“.

Esther Ortega Echevarría, Head of the Medical Writing Specialty Department.